UICMEW | Post Test, Evaluation and Claim Credit UICMEW | Session 2 - Post Test January 22, 2025 University of Illinois Cancer Center Winter CME Series Session 2: Women and GU Cancers Please enter your information: First Name * Last Name * Degree * Institution * Email * City * State * 1. Which of the following is a key benefit of integrating multidisciplinary approaches in managing breast and gynecological cancers? * A. Reducing the cost of cancer treatment B. Improving patient-centered care and outcomes C. Eliminating the need for targeted therapies D. Standardizing treatments across all cancer subtypes 2. Which of the following advancements is essential for improving outcomes in renal and urothelial cancers? * A. Incorporating traditional chemotherapy as the primary treatment B. Utilizing targeted therapies based on molecular and genetic profiling C. Standardizing treatment protocols across all cancer subtypes D. Avoiding precision medicine to reduce costs 3. Which of the following is critical for the effective integration of newly approved therapies into clinical practice? * A. Prioritizing traditional treatment methods over newer approaches B. Recognizing and managing treatment-related side effects C. Avoiding the use of diagnostics in personalized treatments D. CBC risk is high enough to qualify for MRI screening as an adjunct to mammograph for premenopausal CHEK2 carriers with ER-negative tumors and premenopausal PALB2 carriers with ER-positive tumors. 4. What is the importance of precision medicine in managing prostate cancer, as discussed in Dr. Mohammad Atiq’s session? * A. To promote uniform treatment options for all patients B. To identify diagnostic advancements irrelevant to treatment C. To tailor treatments to the genetic profile of individual patients D. To minimize the role of multidisciplinary care in treatment 5. Why is education on new diagnostics and treatments in renal, urothelial, and prostate cancers critical for oncology clinicians? * A. To reduce reliance on surgical interventions B. To improve personalized treatment strategies for patients C. To simplify the management of breast cancer subtypes D. To promote the use of older therapeutic methods 6. A 62-year-old male with a history of smoking and hypertension presents with hematuria and weight loss. Imaging reveals a mass in the left kidney consistent with renal cell carcinoma. Genetic testing identifies a mutation in the VHL gene. Based on recent advancements in precision medicine, what would be the most appropriate initial treatment strategy? * A. Initiate standard chemotherapy regimen B. Consider immune checkpoint inhibitors targeting PD-1/PD-L1 pathways C. Proceed with surgical resection without systemic therapy D. Recommend radiotherapy as the sole treatment modality Submit If you are human, leave this field blank. Δ
